TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05200585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Liver/Hígado Sano program
Description: The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual standard of care
Description: Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
Study: NCT05902949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heel group
Description: The heel pad group will be applied a plantar support during the months of the study.
Study: NCT04917640

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Either SBRT or IMRT radiation therapy

Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Either SBRT or IMRT radiation therapy
Study: NCT06310811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 Cells injection
Description: Patient will be treated with RD06-04 cells when enrolled in the study
Study: NCT06310018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis
Description: Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (treated with a total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours for first 10 patients followed by 50 patients treated with total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system
Study: NCT06461169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball
Description: Patients squeeze the stress ball
Study: NCT04806269

Intervention type: DEVICE
Intervention: Fitbit and Glandy
Description: Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.

Intervention type: DEVICE
Intervention: Fitbit and Glandy
Description: Data collection from wearable devices (Fitbit Inspire 2 TM) and a mobile app (Glandy TM) Fitbit collects user's heart rate, activity, and sleep data. Glandy collects user's subjective symptom scores.
Study: NCT03964389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Description: A lecture on neuroscience education (EN). The aim of this intervention is to provide participants with information in a clear and simple way so that patients can change their attitude to pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without tissue damage or with damage that justifies the perceived disproportion of pain.
Study: NCT03361852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo Vax
Description: Neo Vax is an experimental viral mimic and an activator of immunity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo Vax
Description: Neo Vax is an experimental viral mimic and an activator of immunity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
Study: NCT06131606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Patients in the experimental group were told how to use the stress ball before the procedure. The patient was then taken to the angiography unit. The stress ball was placed on the palms of the patients according to the procedure position. During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes. After the procedure, the NRS and STAI were filled out as a post-test 10 minutes after the patient was taken to the ward. The answers given by the patients were recorded by the researcher by marking them on the forms.
Study: NCT06451133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MAP) goal of ≥65 mmHg
Description: The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MAP) goal of 85-90 mmHg
Description: The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg
Description: The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.
Study: NCT06259578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
Description: 1 dose of 0.5 ml containing inactivated SARS-CoV-2 virus (5 μg ), Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride
Study: NCT05324085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Supervised exercise intervention, three times a week for eight weeks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
Study: NCT04920942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.4mg/kg/day for 5 days
Description: Ivermectin 0.4mg/kg/day for 5 days with standard-of-care
Study: NCT04768855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered IV or SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered SC.
Study: NCT04818008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: A Home-based Exercise Program to improve strength and balance and prevent falls.
Study: NCT05476393

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative management
Description: 1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative management
Description: 1 g paracetamol will be administered 3 x 1. If the NRS score is ≥ 4, 1 mg kg-1 iv tramadol will be administrated.
Study: NCT06382675

Intervention type: DEVICE
Group type: OTHER
Intervention: Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2
Description: 272 evaluable TPE treatments will be documented in the study (with an average of 5-7 TPE treatments per patient this corresponds to approximately 46 patients)
Study: NCT05705830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse magnetic therapy
Description: Pulse magnetic therapy SM-II (2019102133903)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors （SSRI）
Description: Anti-anxiety Drugs

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Selective serotonin reuptake inhibitors （SSRI）
Description: Anti-anxiety Drugs

Intervention type: DEVICE
Group type: OTHER
Intervention: Shame magnetic therapy
Description: Shame magnetic therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Shame magnetic therapy
Description: Shame magnetic therapy
Study: NCT05293665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 (100µg), 0.5mL suspension, intramuscular injection
Study: NCT04247516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-intervention group I (IGI)
Description: Narrative-based online intervention program to promote self-regulatory competences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-intervention group II (IGII)
Description: Narrative-based online intervention program to promote self-regulatory competencies plus gamification strategies.
Study: NCT06385171

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
Study: NCT05293665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 (100µg), 0.5mL suspension, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 (100µg), 0.5mL suspension, intramuscular injection
Study: NCT05256823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Patients will be treated with Celecoxib twice daily for 48 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: nucleos(t)ide analogue
Description: Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nucleos(t)ide analogue
Description: Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
Study: NCT04827277

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Total Shoulder Replacement
Description: Participants will be randomized to a reverse total shoulder replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomic Total Shoulder Replacement
Description: Participants will be randomized to an anatomic total shoulder replacement
Study: NCT05293665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 (100µg), 0.5mL suspension, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 vaccine
Description: BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
Study: NCT05660096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cionic Neural Sleeve NS-100
Description: Sleeve applies neuromuscular stimulation as patients walk to help contract appropriate muscles at appropriate times.
Study: NCT06521970

Intervention type: DIAGNOSTIC_TEST
Intervention: The kyphosis angle
Description: The subject was positioned in a neutral standing position. the short side of the phone was placed on the T1-3 spinous process and the protractor was set to 0°. Subsequently, the phone was placed on the T12, and the angular value displayed on the screen was recorded as the kyphotic angle.

Intervention type: DIAGNOSTIC_TEST
Intervention: The kyphosis angle
Description: The subject was positioned in a neutral standing position. the short side of the phone was placed on the T1-3 spinous process and the protractor was set to 0°. Subsequently, the phone was placed on the T12, and the angular value displayed on the screen was recorded as the kyphotic angle.

Intervention type: DIAGNOSTIC_TEST
Intervention: dynamic postural performance
Description: The test measures spinal alignment deviations during static loading in the 90° shoulder flexion position. The test measurements are made in a standing position with arms 90° flexed, without weight, and after 30 seconds with weight.

Intervention type: DIAGNOSTIC_TEST
Intervention: dynamic postural performance
Description: The test measures spinal alignment deviations during static loading in the 90° shoulder flexion position. The test measurements are made in a standing position with arms 90° flexed, without weight, and after 30 seconds with weight.
Study: NCT05293665

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 vaccine
Description: BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1-S vaccine
Description: ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
Study: NCT06521970

Intervention type: DIAGNOSTIC_TEST
Intervention: forward head position
Description: The individual stands with his heels and pelvis in contact with the wall. The severity of kyphosis is interpreted by measuring the distance between the occiput and the wall in cm with the head facing forward. The intensity of kyphosis is classified as mild (≤5 cm), moderate (5.1-8 cm) and severe (\>8 cm)
Study: NCT05293665

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm BIBP
Description: Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
Study: NCT05794815

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
Study: NCT04701619

Intervention type: OTHER
Group type: OTHER
Intervention: Immuno-inflammatory profile description in patients with ischemic stroke
Description: Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
Study: NCT05827913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polylevolactic Acid Injection
Description: The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1565nm Non-ablative Fractional Laser
Description: M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser
Description: combination of the two treatments described above
Study: NCT05504252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Q2W~Nivolumab: 240 mg fixed dose over 30 minutes, IV administration every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: FLOX, Q2W
Study: NCT04969068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS\>75 and MOAA/S \> 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
Study: NCT04044898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 5%
Description: prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA 10%
Description: prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose
Study: NCT05335746

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography (OCT-A)
Description: Optical coherence tomography angiography scanning will be done for all subjects in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography (OCT-A)
Description: Optical coherence tomography angiography scanning will be done for all subjects in the study.
Study: NCT05312164

Intervention type: DEVICE
Intervention: HF-OCT Imaging
Description: Subjects undergo HF-OCT imaging of stenosed coronary arteries

Intervention type: DEVICE
Intervention: FFR Pressure Wire
Description: Subjects undergo FFR physiology assessment of stenosed coronary arteries

Intervention type: DEVICE
Intervention: Angiography
Description: Subjects undergo angiography imaging of stenosed coronary arteries
Study: NCT06470997

Intervention type: BIOLOGICAL
Intervention: Blood sample collection
Description: 6 collections of 5mL blood samples as part of usual care (pre-inclusion visit at Day-7, inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months) and 5 blood sample collections of 5 mL for proteomic analysis in the context of research (inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months)

Intervention type: BIOLOGICAL
Intervention: Blood sample collection
Description: 6 collections of 5mL blood samples as part of usual care (pre-inclusion visit at Day-7, inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months) and 5 blood sample collections of 5 mL for proteomic analysis in the context of research (inclusion visit at Day 0, visit1 at Day 14, visit2 at Day 28, visit3 at Day 90, visit4 at 6 months)

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: 1 liver biopsy performed as part of routine care and 1 additional sample for research: transparietal needle biopsy under ultrasound identification under local anesthesia by a radiologist, 1 to 2 cm per core taken, 2 cores are taken.

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: 1 liver biopsy performed as part of routine care and 1 additional sample for research: transparietal needle biopsy under ultrasound identification under local anesthesia by a radiologist, 1 to 2 cm per core taken, 2 cores are taken.
Study: NCT05794815

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
Study: NCT05242952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaming in a virtual environment
Description: To address the primary outcomes of feasibility and acceptability of the VE, we will capture process data using a computer-based virtual environment and self-report measures using an online survey.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gaming in a virtual environment
Description: To address the primary outcomes of feasibility and acceptability of the VE, we will capture process data using a computer-based virtual environment and self-report measures using an online survey.
Study: NCT05253794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: oral tablet daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet daily for 6 months
Study: NCT05684341

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Connected Solution with H2S app which connects with blood glucose meter (BGM)
Description: Combination of the Insultrate titration module software, the H2S app for participants, and the H2S platform for healthcare professionals
Study: NCT04961437

Intervention type: OTHER
Intervention: Diaphragmatic ultrasound and electrical impedance tomography
Description: A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured.~- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography.
Study: NCT05239663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganglioside-Monosialic Acid
Description: Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus Ganglioside-Monosialic Acid 100mg+250ml normal saline (NS)

Intervention type: DRUG
Group type: OTHER
Intervention: 250ml normal saline (NS)
Description: Standard (neo)adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus 250ml normal saline (NS)